Revive Therapeutics and Havn Life Science Enter Into Psychedelic Partnership Agreement

Name: Revive Therapeutics and Havn Life Science Enter Into Psychedelic Partnership Agreement
Uploaded: 2020-10-20
Channel: Shadd Dales
Description: Tim Moore CEO of Havn Life Science CSE: HAVN and Derrick Welsh Strategic Advisor to Revive Therapeutics CSE: RVV joined us talk about their recent psychedelic partnership agreement that both companies have entered into. Based on the partnership the t

By Shadd Dales On Oct 20, 2020

Tim Moore CEO of Havn Life Science CSE: HAVN and Derrick Welsh Strategic Advisor to Revive Therapeutics CSE: RVV joined us talk about their recent psychedelic partnership agreement that both companies have entered into.

Based on the partnership the two companies have signed an agreement for supply of psychedelic compounds and usage to be used for ongoing research.

Revive Therapeutics intends to research both synthetic and natural derived psilocybin with the University of Wisconsin Madison. Natural derived psilocybin’s in the oral thin film technology is a leading trend within the psychedelic industry.

Shadd Dales

Shadd Dales is the Founder and President of The Dales Report and has an extensive background in the business media industry.

His work translates into over 15 years in mainstream media that included roles with BNN Bloomberg, CTV Properties and the iHeart Radio Network.

Shadd is considered one of the leading on air talents in both the cannabis and psychedelic space and has interviewed some of the most notable CEO names in the industry.

Shadd’s vision is to establish a content platform that is equivalent to a mainstream broadcast produced in a format that is relevant for today’s investor.